Prime medicine to present preclinical data demonstrating broad potential of prime editing technology at upcoming scientific meetings

-- presentations include new preclinical data for pm359, further demonstrating ability of prime editors to efficiently, reproducibly and durably correct causative mutation of cgd; on track to enter clinical development in 2024, with initial data expected in 2025 -- -- prime medicine co-founder, david liu, ph.d., awarded asgct outstanding achievement award --
PRME Ratings Summary
PRME Quant Ranking